Published • loading... • Updated
Neurosense, Health Canada discuss approval path for PrimeC
Summary by ALS News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Neurosense, Health Canada discuss approval path for PrimeC
Neurosense Therapeutics said it recently held a “constructive” meeting with Health Canada to discuss potential regulatory pathways for PrimeC, its experimental oral therapy for amyotrophic lateral sclerosis (ALS). The meeting focused on the company’s proposed new drug submission (NDS) strategy and the clinical, biomarker, and long-term outcomes data supporting a potential application for PrimeC, Neurosense said in a U.S. Securities and Exchange …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
